Long-term Platinum Retention After Cisplatin and Oxaliplatin Treatment
Author Information
Author(s): Brouwers Elke EM, Huitema Alwin DR, Beijnen Jos H, Schellens Jan HM
Primary Institution: Slotervaart Hospital/The Netherlands Cancer Institute
Hypothesis
The study aims to evaluate long-term platinum retention in patients treated with cisplatin and oxaliplatin.
Conclusion
Plasma platinum levels are related to time, age, dose, GFR, and STS use, with some platinum species in plasma ultrafiltrate remaining reactive.
Supporting Evidence
- Platinum plasma concentrations ranged between 142–2.99 × 103 ng/L.
- Up to 24% of plasma platinum was recovered in plasma ultrafiltrate.
- No platinum-DNA adducts in peripheral blood mononuclear cells could be detected.
Takeaway
This study looked at how long platinum from cancer treatments stays in the body and found that it can stay for a long time and still be active.
Methodology
The study measured platinum levels in plasma and plasma ultrafiltrate from patients treated with cisplatin and oxaliplatin, analyzing relationships with various factors.
Limitations
The study could not establish the chemical composition of platinum species in plasma ultrafiltrate.
Participant Demographics
Participants included 13 males and 7 females treated with cisplatin, and 20 males and 5 females treated with oxaliplatin, with a median age of 49 years for cisplatin and 64 years for oxaliplatin.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website